Breaking News

Moleculin Selects IQVIA Biotech to Advance COVID Treatment

IQVIA to manage the company's effort to begin potential clinical trials of WP1122 for the treatment of COVID-19.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Moleculin Biotech, Inc., a clinical stage pharmaceutical company with a portfolio of drug candidates targeting highly resistant tumors and viruses, has selected IQVIA Biotech, a CRO, to manage the company’s effort to begin potential clinical trials of WP1122 for the treatment of COVID-19.   “Our teaming up with IQVIA, a preeminent, global CRO, is intended to facilitate the advancement into possible clinical trials for WP1122 with the objective of determining our drug’s potent...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters